The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | A national cancer nurse education needs assessment in the UK on bispecific antibody therapy
Chantelle Hughes, RN, MScN, University College London Hospitals, London, UK, shares insights from a national cancer nurse education needs assessment in the UK on bispecific antibody therapy. She highlights that a national survey showed nurses lacked confidence in identifying and managing toxicities associated with bispecifics, and discusses how training should be delivered. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Bi-specific antibodies are relatively newly available within our National Health Service and some earlier work had identified that healthcare professionals have limited experience with them up to now, especially at the smaller hospitals. Nurses being one of the largest workforce and those most often involved in the direct care of these patients I wanted to see what the level of confidence was with cancer nurses across the UK but also find out how they wanted training to be delivered like what actually worked for them...
Bi-specific antibodies are relatively newly available within our National Health Service and some earlier work had identified that healthcare professionals have limited experience with them up to now, especially at the smaller hospitals. Nurses being one of the largest workforce and those most often involved in the direct care of these patients I wanted to see what the level of confidence was with cancer nurses across the UK but also find out how they wanted training to be delivered like what actually worked for them. So I did a national survey going out through our professional links and through connections I’ve got across the country. And we heard from around 130 nurses. And what we heard was that actually nurses aren’t very confident with bispecific antibodies. Around 20% said they weren’t confident in identifying the side effects and toxicities common with this drug group. And around a third said that they weren’t confident in managing those toxicities. And around a quarter said that they weren’t confident in talking to patients about what to expect from these drugs and side effects and what medicines they needed to take alongside bispecific antibodies to reduce the risks of these drugs. When it came to training preferences, people overwhelmingly prefer in-person. However, nurses acknowledge that getting time and funding to attend in-person events is challenging. So the next best option was e-learning using case scenarios to support learning and short videos. So we have taken this work and we’ve worked with Myeloma UK, one of our charities, to produce a nurse guide for bispecific antibodies, so an easy access resource, which was published earlier this week. And we’ve also are seeking funding to design this kind of accessible e-learning in a bite-sized way that nurses will actually be able to fit around their commitments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
